Aspect Biosystems Secures $115 Million for Bioprinted Tissue Therapeutics
Aspect Biosystems, a pioneering biotechnology company in the field of bioprinted tissue therapeutics, has recently secured a significant funding round to advance its mission of transforming how we treat serious diseases. The company announced that it has closed a US$115 million Series B financing round, led by Dimension, a multistage investment firm dedicated to the interface of technology and the life sciences.
This financing round builds on Aspect’s recent momentum, including a CA$200 million partnership with the governments of Canada and British Columbia and a partnership with Novo Nordisk focused on diabetes and obesity. The proceeds from the Series B will enable Aspect to advance multiple bioprinted tissue therapeutics towards the clinic, with a mission to deliver a new class of cellular medicines and functional cures for people living with serious metabolic and endocrine diseases.
Aspect Biosystems is at the forefront of developing bioprinted tissue therapeutics as a new category in regenerative medicine. The company’s full-stack tissue therapeutic platform integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. This platform allows for the creation of living human tissues with unprecedented control, flexibility, and precision, which can be used to replace, repair, or supplement biological function inside the body.
The funding will also fuel the expansion of Aspect’s industry-leading platform, which has the potential to shape every aspect of human health by enabling the creation of human tissues for medical research, therapeutic discovery, and regenerative medicine. The company is advancing a pipeline of bioprinted tissue therapeutics across multiple disease areas in the endocrine and metabolic space, including diabetes, obesity, rare endocrine disorders, and liver disease.
Tamer Mohamed, Founder and CEO of Aspect Biosystems, expressed his pride in the progress the team is making on their mission to develop disease-modifying treatments for people living with serious diseases. “We are thrilled to partner with Dimension and this exceptional, mission-aligned investor syndicate. We are grateful for their support as we embark on our next chapter dedicated to transforming patient outcomes for the better,” he stated.
Nan Li, Founder & Managing Partner at Dimension, was appointed to the Company’s Board of Directors concurrent with the financing. “Aspect is an embodiment of the multi-disciplinary companies that we believe will define the next chapter of biotech,” he said. “The company brings together capabilities across tissue engineering, cell therapy, biomaterials, computer vision, and robotics to deliver on the promise of regenerative medicine. We are beyond excited to partner with the Aspect team to advance their programs forward and to build a generational company.”
The Series B financing round was participated in by existing and new investors, including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture. This significant investment underscores the confidence in Aspect Biosystems’ innovative approach to bioprinted tissue therapeutics and its potential to revolutionize healthcare by developing functional cures for serious diseases.
See more funded startups in USA.